ASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancer 05 Jun 2019 A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Find out more Show/Hide
Sutton MP – Paul Scully – becomes cancer researcher for the day at the ICR 21 Mar 2019 Local MP Paul Scully donned a lab coat and safety specs to spend a day as a cancer researcher working in the Sutton laboratories of the ICR. Find out more Show/Hide
The ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancer 18 Oct 2018 The ICR strongly welcomes the news that talazoparib (trade name Talzenna) has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer. Find out more Show/Hide
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018